vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and PEGASYSTEMS INC (PEGA). Click either name above to swap in a different company.
PEGASYSTEMS INC is the larger business by last-quarter revenue ($430.0M vs $339.0M, roughly 1.3× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs 7.6%, a 5.6% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -9.6%). PEGASYSTEMS INC produced more free cash flow last quarter ($206.5M vs $87.2M). Over the past eight quarters, PEGASYSTEMS INC's revenue compounded faster (10.7% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Pegasystems Inc. (Pega) is a global software company based in Waltham, Massachusetts, in the United States, and founded in 1983. The company has been publicly traded since 1996 as PEGA (NASDAQ). Pega is a low-code platform for workflow automation and generative AI-powered decision-making for businesses.
HAE vs PEGA — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $430.0M |
| Net Profit | $44.7M | $32.8M |
| Gross Margin | 59.7% | 75.2% |
| Operating Margin | 19.9% | 8.6% |
| Net Margin | 13.2% | 7.6% |
| Revenue YoY | -2.7% | -9.6% |
| Net Profit YoY | 19.3% | — |
| EPS (diluted) | $0.95 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $430.0M | ||
| Q4 25 | $339.0M | $504.3M | ||
| Q3 25 | $327.3M | $381.4M | ||
| Q2 25 | $321.4M | $384.5M | ||
| Q1 25 | $330.6M | $475.6M | ||
| Q4 24 | $348.5M | $490.8M | ||
| Q3 24 | $345.5M | $325.1M | ||
| Q2 24 | $336.2M | $351.2M |
| Q1 26 | — | $32.8M | ||
| Q4 25 | $44.7M | $234.6M | ||
| Q3 25 | $38.7M | $43.4M | ||
| Q2 25 | $34.0M | $30.1M | ||
| Q1 25 | $58.0M | $85.4M | ||
| Q4 24 | $37.5M | $119.1M | ||
| Q3 24 | $33.8M | $-14.4M | ||
| Q2 24 | $38.4M | $6.6M |
| Q1 26 | — | 75.2% | ||
| Q4 25 | 59.7% | 79.5% | ||
| Q3 25 | 59.5% | 72.2% | ||
| Q2 25 | 59.8% | 71.5% | ||
| Q1 25 | 58.4% | 78.5% | ||
| Q4 24 | 55.5% | 79.1% | ||
| Q3 24 | 54.2% | 70.2% | ||
| Q2 24 | 52.0% | 72.4% |
| Q1 26 | — | 8.6% | ||
| Q4 25 | 19.9% | 20.7% | ||
| Q3 25 | 17.9% | 3.8% | ||
| Q2 25 | 16.8% | 4.5% | ||
| Q1 25 | 21.6% | 26.7% | ||
| Q4 24 | 16.9% | 29.1% | ||
| Q3 24 | 15.0% | -3.6% | ||
| Q2 24 | 11.8% | 3.7% |
| Q1 26 | — | 7.6% | ||
| Q4 25 | 13.2% | 46.5% | ||
| Q3 25 | 11.8% | 11.4% | ||
| Q2 25 | 10.6% | 7.8% | ||
| Q1 25 | 17.5% | 18.0% | ||
| Q4 24 | 10.8% | 24.3% | ||
| Q3 24 | 9.8% | -4.4% | ||
| Q2 24 | 11.4% | 1.9% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $0.95 | $0.81 | ||
| Q3 25 | $0.81 | $0.24 | ||
| Q2 25 | $0.70 | $0.17 | ||
| Q1 25 | $1.17 | $0.91 | ||
| Q4 24 | $0.74 | $1.35 | ||
| Q3 24 | $0.66 | $-0.17 | ||
| Q2 24 | $0.74 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $270.0M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $705.9M |
| Total Assets | $2.5B | $1.6B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $270.0M | ||
| Q4 25 | $363.4M | $425.8M | ||
| Q3 25 | $296.4M | $351.4M | ||
| Q2 25 | $292.9M | $411.6M | ||
| Q1 25 | $306.8M | $371.7M | ||
| Q4 24 | $320.8M | $740.0M | ||
| Q3 24 | $299.3M | $703.0M | ||
| Q2 24 | $344.4M | $665.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $705.9M | ||
| Q4 25 | $911.5M | $787.4M | ||
| Q3 25 | $849.2M | $596.8M | ||
| Q2 25 | $882.3M | $624.5M | ||
| Q1 25 | $820.8M | $611.3M | ||
| Q4 24 | $906.9M | $585.5M | ||
| Q3 24 | $878.9M | $473.0M | ||
| Q2 24 | $905.4M | $435.4M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $2.5B | $1.6B | ||
| Q3 25 | $2.4B | $1.3B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $2.5B | $1.3B | ||
| Q4 24 | $2.5B | $1.8B | ||
| Q3 24 | $2.5B | $1.6B | ||
| Q2 24 | $2.5B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | — |
| Free Cash FlowOCF − Capex | $87.2M | $206.5M |
| FCF MarginFCF / Revenue | 25.7% | 48.0% |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $494.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $93.6M | $158.4M | ||
| Q3 25 | $111.3M | $56.3M | ||
| Q2 25 | $17.4M | $86.3M | ||
| Q1 25 | $116.6M | $204.2M | ||
| Q4 24 | $43.8M | $95.2M | ||
| Q3 24 | $48.8M | $30.5M | ||
| Q2 24 | $-27.4M | $40.1M |
| Q1 26 | — | $206.5M | ||
| Q4 25 | $87.2M | $152.4M | ||
| Q3 25 | $106.3M | $51.8M | ||
| Q2 25 | $13.6M | $84.1M | ||
| Q1 25 | $100.9M | $202.3M | ||
| Q4 24 | $35.2M | $92.4M | ||
| Q3 24 | $39.4M | $27.4M | ||
| Q2 24 | $-33.1M | $38.8M |
| Q1 26 | — | 48.0% | ||
| Q4 25 | 25.7% | 30.2% | ||
| Q3 25 | 32.5% | 13.6% | ||
| Q2 25 | 4.2% | 21.9% | ||
| Q1 25 | 30.5% | 42.5% | ||
| Q4 24 | 10.1% | 18.8% | ||
| Q3 24 | 11.4% | 8.4% | ||
| Q2 24 | -9.8% | 11.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 1.2% | ||
| Q3 25 | 1.5% | 1.2% | ||
| Q2 25 | 1.2% | 0.6% | ||
| Q1 25 | 4.7% | 0.4% | ||
| Q4 24 | 2.5% | 0.6% | ||
| Q3 24 | 2.7% | 0.9% | ||
| Q2 24 | 1.7% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.09× | 0.68× | ||
| Q3 25 | 2.88× | 1.30× | ||
| Q2 25 | 0.51× | 2.87× | ||
| Q1 25 | 2.01× | 2.39× | ||
| Q4 24 | 1.17× | 0.80× | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | 6.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
PEGA
| Pega Cloud | $205.0M | 48% |
| Subscription license | $94.9M | 22% |
| Maintenance | $75.3M | 18% |
| Consulting | $54.8M | 13% |
